Antiplatelet and anticoagulant drugs do not affect visual acuity in the comparing bevacizumab to ranibizumab in age-related macular degeneration (BRAMD) trial

被引：0
|
作者：
Schauwvlieghe, A. M. E. [1 ]
Buitendijk, G. H. S. [1 ]
Dijkman, G. [1 ]
Hoyng, C. [1 ]
Hooymans, J. M. [1 ]
Verbraak, F. D. [1 ]
Vingerling, J. R. [1 ]
Claver, C. C. [1 ]
Schlingemann, R. O. [1 ]
机构：
[1] Acad Med Ctr, Amsterdam, Netherlands
来源：
ACTA OPHTHALMOLOGICA | 2017年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [41] Visual acuity and fixation characteristics in age-related, macular degeneration
    Cacho, Isabel
    Dickinson, Christine M.
    Reeves, Barnaby C.
    Harper, Robert A.
    OPTOMETRY AND VISION SCIENCE, 2007, 84 (06) : 487 - 495
  • [42] Do Intravitreal Ranibizumab Injections for Wet Age-Related Macular Degeneration Affect the Vitreomacular Interface?
    Sreekantam, S.
    Gibson, J. M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [43] Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
    Jun Li
    Han Zhang
    Peng Sun
    Feng Gu
    Zhe-Li Liu
    International Journal of Ophthalmology, 2013, (02) : 169 - 173
  • [44] Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
    Martin, Daniel F.
    Maguire, Maureen G.
    Ying, Gui-shuang
    Grunwald, Juan E.
    Fine, Stuart L.
    Jaffe, Glenn J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (20): : 1897 - 1908
  • [45] Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
    Li, Jun
    Zhang, Han
    Sun, Peng
    Gu, Feng
    Liu, Zhe-Li
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2013, 6 (02) : 169 - 173
  • [46] Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
    Moja, Lorenzo
    Lucenteforte, Ersilia
    Kwag, Koren H.
    Bertele, Vittorio
    Campomori, Annalisa
    Chakravarthy, Usha
    D'Amico, Roberto
    Dickersin, Kay
    Kodjikian, Laurent
    Lindsley, Kristina
    Loke, Yoon
    Maguire, Maureen
    Martin, Daniel F.
    Mugelli, Alessandro
    Muehlbauer, Bernd
    Puentmann, Isabel
    Reeves, Barnaby
    Rogers, Chris
    Schmucker, Christine
    Subramanian, Manju L.
    Virgili, Gianni
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (09):
  • [47] Bevacizumab and ranibizumab in exudative age-related macular degeneration: Is the effectiveness conditioned by accessibility?
    Luna Pinto, Jose
    Real, Juan
    Urrets-Zavalia, Julio
    Juarez, Claudio
    Palma, Santiago
    Granero, Gladys
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [48] Age-related Macular Degeneration Large Cost Difference between Bevacizumab and Ranibizumab
    Post, Antonie
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (04) : 345 - 345
  • [49] Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration A Multicenter, Retrospective Study
    Fong, Donald S.
    Custis, Peter
    Howes, Jennifer
    Hsu, Jin-Wen
    OPHTHALMOLOGY, 2010, 117 (02) : 298 - 302
  • [50] Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
    Bakall, Benjamin
    Folk, James C.
    Boldt, H. Culver
    Sohn, Elliott H.
    Stone, Edwin M.
    Russell, Stephen R.
    Mahajan, Vinit B.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (01) : 15 - 22
12345